[1]黎丽娜,侯建峰,杜娟,等.祛痰化瘀补肾方辅助TCRA对宫腔粘连患者TGF-β1及Smad2/3表达的影响[J].西部中医药,2025,38(01):147-150.[doi:10.12174/j.issn.2096-9600.2025.01.30]
　LI Lina,HOU Jianfeng,DU Juan,et al.Effects of Phlegm-removing Stasis-resolving Kidney-Tonifying Prescription as Adjunctive Therapy of TCRA on the Expressions of TGF-β1 and Smad2/3 in Patients with Intrauterine Adhesions[J].Western Journal of Traditional Chinese Medicine,2025,38(01):147-150.[doi:10.12174/j.issn.2096-9600.2025.01.30]
点击复制

祛痰化瘀补肾方辅助TCRA对宫腔粘连患者TGF-β1及Smad2/3表达的影响()
分享到：

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
38
期数:
2025年01期
页码:
147-150
栏目:
衷中参西
出版日期:
2025-01-15

文章信息/Info

Title:
Effects of Phlegm-removing Stasis-resolving Kidney-Tonifying Prescription as Adjunctive Therapy of TCRA on the Expressions of TGF-β1 and Smad2/3 in Patients with Intrauterine Adhesions
作者:
黎丽娜, 侯建峰, 杜娟, 李丽慧, 钟文珍, 张潇涵, 吴怡平
广东省中医院珠海医院，广东 珠海 519000
Author(s):
LI Lina, HOU Jianfeng, DU Juan, LI Lihui, ZHONG Wenzhen, ZHANG Xiaohan, WU Yiping
Zhuhai Hospital, Guangdong Provincial Hospital of Chinese Medicine, Zhuhai519000, China
关键词:
宫腔粘连; 祛痰化瘀补肾; 转化生长因子; Smad2/3
Keywords:
intrauterine adhesions; phlegm-removing stasis-resolving kidney-tonifying; transforming growth factor-; Smad2/3
分类号:
R271.1
DOI:
10.12174/j.issn.2096-9600.2025.01.30
文献标志码:
B
摘要:
目的观察祛痰化瘀补肾方辅助宫腔镜宫腔粘连分离术（transcervical resection of adhesion，TCRA）治疗宫腔粘连（intrauterine adhesions，IUA）患者粘连组织中转化生长因子β1（transforming growth factor-β1，TGF-β1）、Smad2/3表达的影响。 方法收集IUA患者50例，随机分为试验组30例与对照组20例，两组患者TCRA术后，试验组予中药祛痰化瘀补肾方治疗，对照组予雌孕激素人工周期疗法治疗，治疗2个月后复查宫腔镜。评估两组临床疗效，免疫组化法检测治疗前后粘连组织中TGF-β1与Smad2/3的表达情况。 结果两组治疗后粘连范围、性质、输卵管开口状态、子宫内膜厚度、月经状态评分差异均无统计学意义（P＞0.05）；试验组总有效率［95.0%（19/20）］高于对照组［86.7%（26/30）］，两组比较差异无统计学意义（P＞0.05）。TGF-β1与Smad2/3在IUA组织中阳性表达率高于正常内膜（P＜0.05）。治疗后，患者宫腔恢复正常者治疗组占46.7%（14/30）、对照组占45.0%（9/20），两组比较差异无统计学意义（χ2=0.13，P=0.908）。两组仍有粘连者，治疗后TGF-β1和Smad2/3表达积分均下降（P＜0.05），但两组下降幅度比较，差异无统计学意义（P＞0.05）。 结论祛痰化瘀补肾方辅助TCRA治疗IUA临床疗效与雌孕激素人工周期效果相当，对TGF-β1、Smad2/3表达的影响与雌孕激素人工周期治疗接近；调节TGF-β1/Smad信号通路是祛痰化瘀补肾方治疗IUA可能的现代作用机制。
Abstract:
ObjectiveTo observe the influence of phlegm-removing stasis-resolving kidney-tonifying prescrip-tion as adjunctive therapy and transcervical resection of adhesion (TCRA) on the expressions of transforming growth factor-β1(TGF-β1) and Smad2/3 in patients with intrauterine adhesions (IUA). MethodsAll 50 IUA patients were collected and randomized into 30 cases in the test group and 20 cases in the control group, after TCRA, the test group took phlegm-removing stasis-resolving kidney-tonifying prescription orally, and the control group was given artificial cycle therapy with estrogen and progesterone, to recheck hysteroscopy after two months of the treatment. To assess clinical effects in the two groups, immunohistochemistry was used to detect the expressions of TGF-β1 and Smad2/3 in adhesive tissue before and after the treatment. ResultsThe difference had no statistical meaning in the extent and nature of adhesions, state of tubal opening, endometrial thickness and the scores of menstrual state after the treatment between both groups (P>0.05); total effective rate of the test group was [95.0%(19/20)], higher than [86.7%(26/30)] of the control group, and the difference had no statistical meaning (P>0.05). Positive expressions of TGF-β1 and Smad2/3 in the tissue of IUA were higher than these in normal endometrium (P<0.05). After the treatment, the patients whose uterine cavity returns to normal held 46.7% (14/30) in the test group, and 45.0% (9/20) in the control group, and the difference had no statistical meaning (χ2=0.13, P=0.908). For those who still have adhesions in both groups, the scores of TGF-β1 and Smad2/3 expressions lowered after the treatment (P<0.05), while there was no difference in the decrease between both groups (P>0.05). ConclusionPhlegm-removing stasis-resolving kidney-tonifying prescription as adjunctive therapy and TCRA are equivalent to artificial cycle therapy with estrogen and progesterone in the treatment of IUA, the effects on the expressions of TGF-β1 and Smad2/3 are close to these of artificial cycle therapy with estrogen and progesterone. The regulation of TGF-β1/Smad signaling pathway is the potential modern mechanism of the prescription in the treatment of IUA.

备注/Memo

备注/Memo:
黎丽娜（1985—），女，硕士学位，主治医师。研究方向：妇科疾病的中医诊治。广东省中医药局科研项目（20231306）。
更新日期/Last Update: 2025-01-15